Prof. Wang mainly engaged in the clinical and basic research of leukemia. He revealed some mechanisms of leukemogenesis and a series of therapeutic targets for leukemia. He established a clinical research system for hematologic diseases, designed and conducted clinical trials for leukemia that illustrated of prognostic factors, significantly improved survival of acute leukemia. Prof. Wang designed and developed a lot of chimeric antigen T cell (CAR-T) technologies against leukemia, lymphoma and myeloma with intellectual property. Through phase II trial, CD19 CAR-T (Inaticabtagene Autoleucel) has been approved by National Medical Products Administration for marketing for treatment relapsed or refractory acute lymphoblastic leukemia. He has edited 4 books and published more than 100 peer reviewed papers as first or corresponding author including those in NEJM, PNAS, Blood. 10 invention patents have been authorized.
MS, Internal Medicine, Peking Union Medical College, Beijing, China, 1988-1991
BM, Medicine, Shandong Medical College, Jinan, China, 1980-1985
Professor of Medicine, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1999-
Associate Professor, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1994-1999
Visiting Fellow, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, 1994-1999
Attending Physician, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1991-1994
Resident, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1985-1988
PRINCIPAL HONORS, AWARDS:
1997 NIH Fellows Award for Research Excellence
2008 Wu Jieping - Paul Janssen Medical & Pharmaceutical Award
2020 The First Grade Award of Science and Technology of Tianjin
2021 Second Grade Award of Chinese Medicine
MAJOR NATIONAL LEADERSHIP POSITIONS, SOCIETIES AND BOARDS:
2011-2015 President, Society of Hematologic Malignacies, Chinese Anti-cancer Association
2014-2025 Vice president, Chinese Association of Hematologists
2016-2019 President, Chinese Society of Hematology
2019-2022 Vice president, Chinese Association of Physician
SELECTED PUBLICATIONS:
1. Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP, Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med, 2024, 391(10):885-898.
2. Gong X, Fang Q, Gu R, Qiu S, Liu K, Lin D, Zhou C, Zhang G, Gong B, Liu Y, Li Y, Liu B, Wang Y, Wei H, Mi Y, Wang J*. A pediatric-inspired regimen for adolescent and adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a prospective study from China. Haematologica. 2024, 109(10):3146-3156.
3. Liu X, Liu Y, Rao Q, Mei Y, Xing H, Gu R, Mou J, Chen M, Ding F, Xie W, Tang K, Tian Z, Wang M*, Qiu S*, Wang J*. Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Pre-leukemic Cells. Cancer Res. 2024，84(24):4233-4245.
4. Wang J*, Jiang B, Li J, Liu L, Du X, Jiang H, Hu J, Yuan M, Sakatani T, Kadokura T, Takeuchi M, Kosako M, Ma X, Girshova L, Tan J, Bondarenko S, Wong Lee Lee L, Khuhapinant A, Martynova E, Hasabou N. Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. Leukemia, 2024，38(11):2410-2418.
5. Qiu S, Mei Y, Gu R, Liu Y, Chen M, Xing H, Tang K, Tian Z, Rao Q, Yang D, Pang A, Wei S, Jia Y, Wang H, Feng S, Wei H, Zhu P, Wang M, Wang Y*, Liu W*, Wang J*. The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patients. Leukemia. 2025，39(1):238-242
6. Wang Y, Lv L, Song Y, Wei X, Zhou H, Liu Q, Xu K, Yan D, Zhang C, Liu S, Jin J, Mei H, Niu T, Liang A, Gu R, Ren J, Feng Y, Jin W, Zhou Y, Deng Y, Wang J. Inaticabtagene Autoleucel (CNCT19) in adult relapsed or refractory B-cell acute lymphoblastic leukemia. Blood Adv, 2025, 25;9(4):836-843.
7. Zhang C, Gu R, Wang H, Zhou C, Li Y, Liu Y, Wei S, Lin D, Liu K, Fang Q, Gong X, Gong B, Qiu S, Zhang G, Liu B, Wang Y, Mi Y, Wei H*, Wang J*. Risk stratification in the clinical application of minimal residual disease assessment in acute myeloid leukemia. Cancer, 2025, 1; 131(1): e35641.